Activity of nine fluoroquinolones against strains of Bordetella bronchiseptica

International Journal of Antimicrobial Agents

Volumn 12, Issue 4, 1999, Pages 355-358

  Carbone, Maria ^a   Fera, Maria Teresa ^a   Pennisi, Maria Grazia ^a   Masucci, Marisa ^a   De Sarro, Angela ^a   Macrì, Concetta ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Bordetella bronchiseptica; Fluoroquinolones

Indexed keywords

CIPROFLOXACIN; ENOXACIN; FLEROXACIN; LOMEFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUFLOXACIN; TEMAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BORDETELLA BRONCHISEPTICA; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFECTIVE AGENTS; BORDETELLA BRONCHISEPTICA; CATS; FEMALE; FLUOROQUINOLONES; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 0033178977     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00077-1     Document Type: Article

References (27)

1. Bemis D.A., Greisen H.A., Appel M.J.G. Pathogenesis of canine bordetellosis. J. Infect. Dis. 135:1977;753-762.
2. Dixon M., Jackson D.M., Richards I.M. The effect of a respiratory tract infection on histamine-induced changes in lung mechanics and irritant receptor discharge in dogs. Am. Rev. Resp. Dis. 120:1979;843-848.
3. Goodnow R.A. Biology of Bordetella bronchiseptica. Microbiol. Rev. 44:1980;722-738.
4. Little T.W.A. Respiratory disease in pigs: a study. Vet. Rec. 96:1975;540-544.
5. Snyder S.B., Fish S.K., Fox J.G., Soave O.A. Respiratory tract disease associated with Bordetella bronchiseptica infection in cats. J.A.V.M.A. 163:1973;293-294.
6. Thayer G.W. Canine infectious tracheobronchitis. Greene C.E. Clinical Microbiology and Infectious Diseases of the Dog and Cat. 1984;430-436 Saunders, Philadelphia.
7. Willoughby K., Dawson S., Jones R.C. et al. Isolation of B. bronchiseptica from kittens with pneumonia in a breeding cattery. Vet. Rec. 129:1991;407-408.
8. Kloos W.E., Mohapatra N., Dobrogosz W.J., Ezzell J.W., Manclark C.R. Deoxyribonucleotide sequence relationships among Bordetella species. Int. J. Syst. Bacteriol. 31:1981;173-176.
9. Delafuente J., Albo C., Rodriguez A., Sopena B., Martinez C. Bordetella bronchiseptica pneumonia in a patient with AIDS. Thorax. 49:1994;719-720.
10. Meis J.F.G.M., van Griethuijsen A.J.A., Muytjens H.L. Bordetella bronchiseptica bronchitis in an immunosuppressed patient, 1990. Eur. J. Clin. Microbiol. Infect. Dis. 9:1990;366-367.
11. Mesnard R., Guiso N., Michelet C. et al. Isolation of Bordetella bronchiseptica from a patient with AIDS. Eur. J. Clin. Microbiol. Infect. Dis. 12:1993;304-306.
12. Bauwens J.E., Spach D.H., Schacker T.W., Mustafa M.M., Bowden R.A. Bordetella brochiseptica pneumonia and bacteremia following bone marrow transplantation. J. Clin. Microbiol. 30:1992;2474-2475.
13. Ghosh H.K., Tranter J. Bordetella bronchicanis (bronchiseptica) infection in man: review and a case report. J. Clin. Pathol. 32:1979;546-548.
14. Gueirard P., Weber C., Le Coustumier A., Guiso N. Human Bordetella bronchiseptica infection related to contact with infected animals: persistence of bacteria in host. J. Clin. Microbiol. 33:1995;2002-2006.
15. Woolfrey B.F., Moody J.A. Human infections associated with Bordetella bronchiseptica. Clin. Microbiol. Rev. 4:1991;243-255.
16. Switzer W.P., Maré C.J., Hubbard E.D. Incidence of Bordetella bronchiseptica in wildlife and man in Iowa. Am. J. Vet. Res. 27:1966;1134-1136.
17. Jacobs A.A.C., Chalmers W.S.K., Pasman J., van Vugt F., Cuenen L.H. Feline bordetellosis: challenge and vaccine studies. Vet. Rec. 133:1993;260-263.
18. Kurzynski T.A., Boehm D.M., Rott-Petri J.A., Schell R.F., Allison P.E. Antimicrobial susceptibilities of Bordetella species isolated in a multicenter pertussis surveillance project. Antimicrob. Agents Chemother. 32:1988;137-140.
19. Mortensen J.E., Brumbach A., Shryock T.R. Antimicrobial susceptibility of Bordetella avium and Bordetella bronchiseptica isolates. Antimicrob. Agents Chemother. 33:1989;771-772.
20. Speakman A.J., Binns S.H., Dawson S., Hart C.A., Gaskell R.M. Antimicrobial susceptibility of Bordetella bronchiseptica isolates from cats and a comparison of the agar dilution and E-test methods. Vet. Microbiol. 54:1997;63-72.
21. Hannan P.C.T., O'Hanlon P.J., Rogers N.H. In vitro evaluation of various quinolone antibacterial agents against veterinary mycoplasmas and porcine respiratory bacterial pathogens. Res. Vet. Sci. 46:1989;202-211.
22. Andriole V.T. Clinical overview of the newer 4-quinolone antibacterial agents. Andriole V.T. The Quinolones. 1988;155-200 Academic Press, New York.
23. Lode H., Höffken G., Bocckk M., Deppermann N., Borner K., Koeppe P. Quinolone pharmacokinetics and metabolism. J. Antimicrob. Chemother. 26:1990;41-49.
24. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Fourth edition. Publication M7-A2. Villanova, PA:National Committee for Clinical Laboratory Standards, 1997.
25. Statement 1996 CA-SFM. Zone sizes and MIC breakpoints for non-fastidious organisms. Clin Microbiol Infect 1996;2:46-8.
26. Phillips I., Baquero F., Bergan T., Degener J., Schito G.C., Wiedemann B. European Study Group on Antibiotic Breakpoints. Breakpoint Determination: Rufloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 12:1993;574-575.
27. Southern P.M. Jr., Patel S. In vitro susceptibility of anaerobic bacteria to temafloxacin. Clin. Infect. Dis. 16:1993;334.